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NTERNATIONAL DISPARITIES PANEL

Professor Sean Flynn:* I am the Associate Director
of the Program on Information Justice and Intellectual

Property program at Washington College of Law
(PIJIP). One of PIJIP's activities is focused on public
policy solutions to the problems created by the
globalization of patents on pharmaceutical products,
particularly in underdeveloped countries.
I want discuss access to medicine disparities in
developing countries and the link between those
disparities and the globalization of patents with the
World Trade Organization. I will talk about what we
call the "access to medicines movement," which is an
international movement of global health advocates that
is focused on the problems and policy solutions that lie
at the intersection of intellectual property, trade policy
and the right to health.
The access to medicine movement addresses a basic
problem: purchasing medicine can be very expensive,
but it does not have to be because making medicines
is often incredibly cheap. The actual manufacturing
process of creating a pill is very inexpensive. An
individual pill often contains a very small dose of
pharmaceutically active ingredients. The cost of the
component chemicals is minor. What is costly is the
research and development that goes into the initial
invention of that drug.
So what we have in pharmaceuticals is an industry
that presents very low marginal costs - the cost of
making that next pill - but high fixed costs - the cost
of inventing the pill and setting up the manufacturing
infrastructure. That is the problem the patent system
seeks to solve. If you let the market run free, then
new producers will copy the original product and
turn out equivalent products in competition with one
another until prices approximate the marginal cost of
production. That is great for promoting access to the
drugs we have now. But why would you create a new
drug (or other product) if marginal cost pricing is what

you can expect from your research and development
investment?
The patent law solution to the problem is to grant
a monopoly right - what we used to call a franchise
- to be the only seller of a new product for a limited
time. That right to exclude competition allows the
company to charge higher prices and corner all sales
for a period, enabling the company to recoup research
and development costs plus a potential profit premium.
The lure of those supra-competitive profits drives
investments in research and development.

Now, recall the important premise in patent law the franchise is to be limited. To reach the optimum
balance between consumer interests in innovation of
new products and their interest in accessing affordable
products now, the patent right must tailored to the
context. No one I know proposes that patent rights
should run forever in a given industry or be impervious
to all forms of economic regulation that impacts the
price patent holder demands. That would expose
consumers to perpetual monopoly rents, which few if
any economists would endorse as an efficient solution
for consumers or the economy more generally.
Now for the second premise: patents pose pricing
problems in all industries, but the problems (and
therefore need for tailoring of patent rights) are
particularly evident in markets for pharmaceuticals and
other essential goods.
As we discussed at the onset, in a competitive market
the introduction of new suppliers willing to sell at everlower above-cost prices will force prices down close
to the marginal cost of producing the good. In other
words, the restraint on prices in a well functioning
competitive market is the cost of production.
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Monopoly markets are different. With no additional competitors that can
enter, the restraint on price will be a function of demand instead of cost.
The monopolist will raise its price above cost until any additional increase,
because of the resulting fall off in sales, will be unprofitable. Monopolists
cannot profitably set any price. The maximum profitable price will be
determined by the willingness and ability of the market to pay. In other
words, the maximum profitable price will be a function of the shape and
slope of the demand curve.
Patents on medicine can cause particular problems for two reasons. First,
drug patents often effectively cover the entire product, rather than an input
into a larger product (e.g. a widget in a machine). Where the medicine is
truly innovative in the sense of doing something useful for a particular group
of patients that no other drug can do, then the monopoly created by a drug
patent can be particularly strong. There will be no substitutes consumers
can shift to.
Second, needed medicines are essential goods. Access to medicines is
necessary to enjoy the full scope of the right to health. Without needed
medicines, people will live shorter and less fruitful lives to the disadvantage
of themselves and the societies they live in.
This essential element has two implications, one economic and one moral.
The economic point is that people will be willing to pay very high portions
of their income to access essential products. Imagine how much you
would be willing to pay for access to a life saving medicine. Or how about
water or electricity in your home. In the latter cases, the essential good is
often delivered by a monopoly as well. But we regulate the prices those
monopolies can charge because otherwise they could exact very high prices
for the services. Would you pay twice your current bill to have water in your
home? Three times? Ten times? You might consume less at these prices, but
there is really no substitute you can choose.

As demand curves go, that one is pretty flat. Small price decreases along the
vertical axis will lead to relatively large increases in purchases along the
horizontal axis. This creates a profit maximizing incentive for the monopolist
to decrease prices to sell more units until about 80 to 90 percent of the
population is served, leaving 10 to 20 percent of the consumers as deadweight
loss. That fact can be represented in a second figure, which shows the
number of sales at each price along the demand curve and the total revenue
(along the vertical axis) for each price and quantity sold.

The essential aspect of medicines also brings to the fore a moral component
of policy choices in this area. Where government policy is distributing access
to goods and services needed to actualize human rights and basic welfare
concerns, then equity concerns need to be paramount. If governments can
produce a policy that leads to as much or more of the innovation of the
necessity while increasing access then (morally) it should. And if it can
purchase a good that will demonstrably increase lives and health, then
human rights laws may require that.
Now we are ready for our third premise. The problems with pharmaceutical
patents will be compounded in countries with high income inequality,
which applies to most of what we call the Third World or the group of
underdeveloped countries.
Recall that in the monopoly markets that patents create, price will be a
function of the shape and slope of the demand curve. These factors are in
turn impacted by the degree of income inequality in a market.
Compare two polar cases -Norway (with the greatest income equality) and
South Africa (with the greatest income inequality).
If you assume that the demand curve for an essential good will be driven
by ability rather than willingness to pay, then you can construct the shape
of that curve based on distribution of income. The figure for Norway is
included below.
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The model predicts that in Norway the social cost we will pay for the
incentives to innovate from monopoly provision of the product will be about
ten to twenty percent of the population prices out of the market and therefore
dependent on social provision of some sort (if there is a right to the medicine
in question). Of course in Norway, everyone receives social provision.
Now let us compare this outcome with a demand curve representative of a
country with extremely high income inequality. In South Africa, the top ten
percent of the people earn first world incomes. But after that, the amount of
income in each decile of the population falls off pretty dramatically, creating
along flat tail of the demand curve where people have very low incomes.

with the small segment of national economies being very rich, and long tail
of low income nations where the majority of the world's population lives.
This leads to the so-called 10/90 gap. The rough-hand trope is meant
to convey that something like ninety percent of global research and
development investment on medicines serves the needs of just ten percent
of the world's population.
Consider the distribution of Dengue fever, which affects about a million
people a year.

This creates very different pricing incentives for the monopolist. The
demand curve is very steep at the richest segment of the population, meaning
that even large price decreases will not lead to large numbers o increased
sales. Look at the step between the first and second decile. If the company
halves its price it will still be too expensive to reach the next segment of
demand. The company would have to decrease its price to about 25% to
double its sales - not a profitable choice.
The profit maximizing behavior of the company can be depicted in the chart
below.

Will a company invest in the development of a new treatment for that
disease? What about tuberculosis, malaria, sleeping sickness, etc.
The premises outlined above lead to a modest conclusion. Because of the
particularities of the impact of patents on pharmaceutical products and
of the characteristics of demand in underdeveloped countries with high
inequality of income, one-size-fits-all patent-based solutions to the problem
of incentivizing innovation for medicines in underdeveloped countries
are inappropriate. Patent rights on pharmaceuticals, to the extent they
are granted at all, need to be highly tailored in underdeveloped country
markets and alternative means of incentivizing research and development
for conditions that primarily impact underdeveloped (especially tropical)
countries need to be considered.
The international intellectual property law trend has been in exactly the
opposite direction. The comparative history of protection of patents in the
pharmaceutical industry is one of a myriad of policy tools used to tailor
patent rights on pharmaceutical products:

Essentially, every time the company decreases price to reach a larger
segment of the population, it loses money. So the rational company,
assuming it has no means to price discriminate between consumers, will set
its price to serve the top 10 percent of the population and leave the rest as
deadweight loss.
The last premise was that the price of patents in underdeveloped countries
with high income inequality is likely to be very high. Correlatively, the
contribution to incentives for innovation is likely to be quite low.
If you are choosing a market to innovate for and the reward for innovation
is a monopoly, then who are you going to target - Norway or South Africa?
Global income distribution essentially looks like the South Africa chart -

* In Brazil, Argentina, Switzerland and Japan, pharmaceuticals were
entirely exempted from patent laws until the 1970s or later.
* In the United Kingdom and Canada, there were special compulsory
licensing provisions for pharmaceuticals that allowed governments
to open up access to generic competition for pharmaceutical
products.
* India created a patent regime that only protected the process of
making pharmaceuticals, instead of the end product, which spun
into the largest generic pharmaceutical industry in the world,
where reverse engineering was used to bring competing products
to market in India.
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In the 1970s and 80s the pharmaceutical industry,
largely based in the U.S. and Europe, led a policy drive
to change this state of affairs and globalize patent laws,
specifically for pharmaceuticals. The justification was
that there was free riding by developing countries on the
pharmaceutical research and development expenditures
by the United States and other wealthy countries.
Ultimately, that policy process led to the inclusion of a
specific agreement on intellectual property in the 1994
World Trade Organization Agreement.
The WTO agreement on Trade Related Aspects of
Intellectual Property (TRIPS) was the first international
agreement setting global minimum substantive
standards for intellectual property. All countries are now
required to grant patents on products and processes.
India's process system is out. No discrimination is
allowed by field of technology - which means that
pharmaceutical industry-specific measures will have to
meet additional justificatory burdens.
Post-TRIPS free trade agreements narrowed the
tailoring options and expanded patent rights further.
And now we have the Anti-counterfeiting Trade
Agreement (ACTA) which may limit the ability of
countries to limit remedies for patent enforcement
(e.g. by doing away with injunctions) and may increase
the rights of transit countries to seize drugs and other
products at the border, thereby limiting the free trade in
affordable medications.
We can pause and ask if this was a positive
development. Theoretically, there are good aspects of
the globalization of intellectual property. It addressed
a real free-riding problem regarding what economists
call a "global public good." Everyone benefits from
a new invention, whether you pay for it or not. When
one country pays for the invention of a new medicine,
all countries benefit from it. But should poor countries
who benefit little from intellectual property protection
pay the same - or really more in deadweight loss terms
- than the richest?
If your answer is no, which mine is, then you might join
the campaign to expand "flexibility" in international
IP law and work on thinking up other tools to meet
the challenges of incentivizing innovation. This is the
agenda of the access to medicines movement.
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Professor Margaret Farrell:* I recently took a ten
day trip to Cuba with twenty-seven other health
care professionals. I count myself as a health care
professional because I am a lawyer that works in health
care. The rest of the group were doctors, nutritionists,
social workers, psychiatrists, and mental health
workers, among others. We had a packed itinerary of
visiting health care facilities, hospitals and sanitariums
and talking to professional involved in providing care
in those institutions. I was reflecting on my remarks
about health care disparities in Cuba and it called into
question what health care disparities in Cuba really
are. Is it disparities in access to care or disparities in
outcomes and quality of care? Are we talking about
disparities among Cubans-rich, poor, urban, rural,
minorities? Does the topic include disparities between
Cuban citizens receiving care in Cuba and foreign
visitors receiving care in Cuba, so called medical
tourists? The topic may also include disparities between
Cuba and other countries in the world.
Cuba is geographically isolated-an island the size of
Pennsylvania. It has eleven million people and most of
the population lives in urban settings. The population
is primarily made up of people of European decent.
There is a small population of mixed races that were
immigrants from Haiti-about ten percent of the
population. The primary language is Spanish. Cuba's
major exports are: nickel, sugar, tobacco, shellfish,
coffee and interestingly, doctors. Cuba is a Communist
country and it was overtaken in 1959 by Fidel Castro,
who was then supported by the United States. At the
time of the revolution, there were a fair number of
doctors per capita, but the disparities were great. There
were 6,000 doctors in the country before the revolution,
but about half of them left for Miami after 1959. The
Castro revolution left Cuba with essentially no health
care system and the country was forced to develop a
health care system in isolation.

Cuba is also politically and economically isolated partly by virtue of the U.S. embargo, although the U.S.
embargo gets blamed for more of Cuba's economic
problems than it should. As a result of its isolation,
Cuba can be seen as a Petri dish experiment in how
to create a health care system with few resources.
The first thing that Cuba did after the revolution was
establish medical schools. Most professors left Cuba
after President Batista was overthrown, so students
with little experience, who had just graduated from
the country's only medical school, became the medical
school faculty. Later, foreign doctors joined the faculty
to teach in Havana. Eventually, Cuba developed a
system of six year medical schools located in each
province and an international medical school with
8,000 students - the Latin-American Medical School
in Havana - which draws students from all over Latin
America to train in western medicine.
A three-tier system for delivering health care was
established. In Cuba, health care delivery system is
focused on the family. At the bottom level there are
neighborhood clinics that are staffed by a doctor and a
nurse who are committed to work in the neighborhood
for two years. The doctor lives above the clinic, so he or
she really becomes a part of the community. They see
most of their clinic patients in the mornings, and in the
afternoon, clinic doctors make regular visits to families
to assess their health care needs.. The family is the
basic unit of health care delivery in Cuba. This differs
from the U.S. individual-based health care system.
Doctors visit each family at least once a year The
medical diagnosis is tripartite-physical, mental, and
social health. The doctor examines how well patients
are functioning in their families and communities.
That basic focus on community and social functioning
makes the Cuban delivery system very different.
The statistical outcomes of Cuba's health care system
are truly impressive. Life expectancy in Cuba is a little
bit higher than it is in the U.S. Mortality of children
under five is 6.5 deaths per thousand births in Cuba and
7.6 deaths per thousand in the U.S. In 2009, newborn
deaths in Cuba were five per thousand births, whereas
the number was six deaths per thousand in the U.S.
Cuba also has the lowest incidence and prevalence of
HIV/AIDS of any country in Latin America (and the
highest literacy rate). In Cuba there is one doctor for
every 170 people. In the U.S., we have one doctor for
every 188 people. The World Health Organization
(WHO) calculates Cuba's annual per capita health
expenditure at $229 per person. The U.S. spends
more than $6,000 per person on health care. Although
differences in cost of living and average annual incomes
make a comparison of health care expenditures in the

two countries difficult, there is a vast difference in the
amount of resources that go into Cuba's system.
The neighborhood health system gets much of the
credit. Cuba assumes responsibility for providing health
care for its population. The Cuban Constitution, unlike
the U.S. Constitution, was amended in 1976 to say
that everyone has a right to health protection and care.
Cuba guarantees this right by providing free medical
and hospital care, offering medical service networks,
providing clinics and hospitals with preventative and
specialized treatment centers, and by providing health
publicity campaigns, medication, regular medical
exams, general vaccinations, and other measures to
prevent disease.
Thus, in Cuba, health is a positive Constitutional right
and the state has a corresponding obligation to provide
medical care and treatment to its citizens. Cuba uses the
$229 per person to concentrate on prevention, which
results in the country's very favorable health outcomes.
Doctors in the neighborhood clinics are activists. They
talk in the schools on a regular basis about sanitation
and hygiene, run vaccination campaigns and lead
school children in campaigns to eliminate mosquitoes.
In addition, since it is a Communist country, Cuba can
require their citizens to do things that the U.S. would
have to persuade people to do. For example, loss of
life due to hurricanes is very low because citizens are
required to participate in evacuation drills, are warned
and are evacuated by police. Cuba's low infant and
maternal mortality rates also result from a system of
close monitoring, maternal residences for high risk
mothers, and specialized hospitals. It does not rely on a
mid-wife system since health clinics and hospitals are
accessible even in rural areas. Cuban citizens seem to
feel that they have a civic duty to be healthy and to use
the benefits provided to them free by the State.
Mark Green*: What I would like to do is frame my
comments around a true story. About a month ago, I
had the chance to visit a small hospital on the islands
of Zanzibar called Nizium Mojo. Literally translated
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Nizium Mojo means, one coconut tree. There was a terrible cyclone that
swept over the islands of Zanzibar and wiped out all the trees but a single
coconut tree and that is where they build the hospital. What is really
interesting about Nizium Mojo is not the story of how people survived the
terrible storm but how the people are surviving
the storm of global health challenges each and
everyadaydonrtheoislandspoffZanzibar.romforty-e
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On the day that I was there, just a month ago,
our guide was Dr. Mohammed who is an old
friend of mine from my days as ambassador. Dr.
Mohammed was also the Principal Secretary of
the Ministry of Health and a licensed surgeon.
He took us upstairs to the pediatric ward and as
we were walking in I saw that there were about
fifteen beds. Dr. Mohammed told us that just
three or four years ago, there were three children
for every single bed in that pediatric ward. On
the day that we walked in, there were three
children in the entire ward. The first child had
what Dr. Mohammed called clinical malaria,
not confirmed by a test. The second child was
a truly pathetic sight-sickly thin arms, cheeks
were drawn, eyes open, but unseemly. The
child's eyes had been damaged by Vitamin A deficiency. The third child
that we saw was an even more heart rendering sight. Her skin was so badly
disfigured that as we were walking up to her, she looked like a burned man.
She suffered from severe malnutrition: protein deficiency. Dr. Mohammed
looked at the third child and said, "We can help her." This story drives home
several important lessons about health disparities, global health challenges
and opportunities for change that are out there.
The first lesson is that historic progress is being made right now on a number
global health fronts. As Dr. Mohammed noted, not so long ago, there would
have been three children to a bed-forty-five children per ward, not three.
The good news is that because of the focus on improving interventions and
improving medicines, we have an opportunity in front of us to conquer
some of the diseases that were once believed to be inevitable. If you spend
any time in Africa, you will meet person after person who will say "I am
the oldest," "I was the third born," or "I was the fourth born," because his
brothers and sisters died before him in childbirth. However, we are making
extraordinary progress, particularly in the area of malaria. On the islands of
Zanzibar, 40 percent were infected with malaria just a few years ago, but
today that number is less than half a percent. Many actually believe that by
2015 malaria will be entirely eliminated from the islands of Zanzibar. In
the area of neglected tropical diseases-lymphatic filariasis or elephantiasis
disease-there are now elimination programs for this terrible disease in 44
of the 83 endemic countries. River blindness has already been eliminated
from ten West African countries and there are plans to do so in many other
countries on the continent. We should first feel good about the progress that
has been made and the opportunities that lie ahead.
Secondly, the progress that we are making on diseases like malaria and river
blindness and some of the neglected tropical diseases, free up resources
to take on other global health challenges. Returning to my Zanzibar story,
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often do when we talk about numbers. In most
places in America, a child is generally either
sick or they are healthy. This is not the case in
the impoverished nations of the world. Children
are never quite healthy in those countries. The
child that survives malaria in its earliest days
of life will very likely suffer life-long cognitive
disabilities, or he or she may be weakened
and made vulnerable to other diseases and
illnesses. He or she is already likely to suffer
from malnutrition and unsafe drinking water.
The child may not be suffering from malaria
symptoms, but neither is he strong and ready to
learn.
On my first night as a volunteer teacher in Kenya
some twenty years ago, the school's headmaster
took me to the funeral of one-year-old twin boys who had died of measles.
I could not believe that the children had died of measles. In Kenya, measles
and other complicating factors such as malaria, malnutrition, and parasites
cause children to die.
We talk about combating global health challenges, but we must realize
that global health is not as black and white as we tend to assume. President
Obama's administration has unveiled its global health initiative, designed to
build upon the marvelous programs that are already there. We are trying to
integrate the services that are provided in some of those programs so that
we get stronger health systems to begin with. At Malaria No More, we think
integration is a good idea, particularly in the areas of diagnostics and lab
facilities. When we talk about health where people are most vulnerableplaces like Africa-we cannot look at things in black and white, through
American eyes.
We are living during pretty exciting times in global health. As I was getting
ready to come here today, the story that broke that King Tut died of malaria.
When examined, the mummy was discovered to have a number of afflictions
and malaria was one of them. Some of our global health challenges have
been with us for a long time. We cannot back down from any global
challenge, be it malaria or HIV Organizations that are devoted to global
health must think of ways to expand programs to be most effect and that is
what Malaria No More is trying to do.
Question: What is the reimbursement rate for physicians in Cuba?
Professor Farrell: You will not believe it, but it is $35 a month. Physicians
really want to practice medicine. It is seen as an honor and patriotic duty to
serve the communist government in that way. Nevertheless, the physicians
we met complained about being over worked, as some of their colleagues
had left to practice in other Latin American Countries.

Question: Does Cuba isolate those with HIV?
Professor Farrell: Yes and no. When AIDS was initially discovered in the
1980s Cuba confined people infected with HIV to sanitariums. When the
mechanism of HIV transmission was discovered, those in sanitariums were
allowed to leave, but many preferred to remain where the living conditions
were better than in their communities. Today, it is voluntary. We visited
these sanitariums which were quite adequate with good living conditions.
Many people who decided to stay there now leave during the day to work in
AIDS programs in the city.

Question: The population of Cuba is thirty times less than the U.S.
million to 300 million). Is it not easier to manage the health
population (I11
of a small population, thus explaining Cuba's statistics?
Professor Farrell: That is absolutely right. Additionally, cultural ideologies
and community differences play an important role.
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